| |
|
The E75 HER2/neu peptide vaccine
Cancer Immunol Immunother. 2008 Jun 7. [Epub ahead of print] |
|
| |
|
Monitoring Circulating Tumor Cells in Cancer Vaccine Trials
Hum Vaccin. 2008 Apr 16;4(5). [Epub ahead of print] |
|
| |
|
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Cancer Immunol Immunother. 2008 Apr 8. [Epub ahead of print] |
|
| |
|
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Clin Cancer Res. 2008 Feb 1;14(3):797-803. |
|
| |
|
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study
Ann Surg Oncol. 2007 Dec;14(12):3359-68. Epub 2007 Sep 29. |
|
| |
|
Assessment
of circulating tumor cell (CTC) patterns among disease-free breast cancer
patients vaccinated with a preventive HER2/neu E75-peptide vaccine
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part
I. Vol 25, No. 18S (June 20 Supplement), 2007: 3059 |
|
| |
|
Clinical
and immunologic effects of a HER2/neu (E75) peptide vaccine booster in previously
vaccinated breast cancer patients.
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part
I. Vol 25, No. 18S (June 20 Supplement), 2007: 3014 |
|
| |
|
Mittendorf, Peoples, et. al.
Investigating
the combination of trastuzumab and HER2/neu peptide vaccines for the treatment
of breast cancer
Ann Surg Oncol 13:1085-98, 2006 |
|
| |
|
Mittendorf, Peoples, et. al.
Vaccination
with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading
in patients with early stage breast cancer
Surgery. 2006 Mar;139(3):407-18 |
|
| |
|
Hueman, Peoples, et. al.
Phase
I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention
of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients
Clin Cancer Research 11:7470-7479, 2005 |
|
| |
|
Peoples, et. al.
Clinical
Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk
Breast Cancer Patients
JCO 23: 1-10, 2005 |
|
| |
|
Woll, Ponniah, Peoples, et. al.
Direct
measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring
the in vivo immune response to a HER2/neu vaccine in breast and prostate
cancer patients
J Clin Immunol 24: 449, 2004 |
|
| |
|
Woll, Peoples, et. al.
Preclinical
testing of a peptide-based, HER2/neu vaccine for prostate cancer
Intl. J Oncology 25: 1769-1780, 2004 |
|
| |
|
Murray, Peoples, Ioannides, et. al.
Toxicity,
Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2
Peptide E75 (369 –377) Combined with Granulocyte Macrophage Colony-stimulating
Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer
Clin Cancer Research 8: 3407-3418, 2002 |
|
| |
|
Castilleja, Murray, Ioannides, et. al.
Induction
of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu
Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2
Complex
J Immunology 169:3545-3554, 2002 |
|
| |
|
Anderson, Peoples, Murray, Ioannides, et. al.
Peptide
Priming of Cytolytic Activity to HER-2 Epitope 369–377 in Healthy
Individuals
Clinical Cancer Research 6: 4192-4200, 2000 |
|
